Tag Archive for: #Synaffix

Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive ADC Data

/in

Kyowa Kirin expands the license agreement with one new ADC to a total of three ADC programs Kyowa Kirin also exercises exclusive target option for development and commercialization against an undisclosed ADC targetad technologies to develop up to three next generation conjugates Decisions driven by highly competitive preclinical therapeutic index demonstrated by Kyowa Kirin’s lead […]

Read more

Genmab and Synaffix Enter into License Agreement for ADC Technology

/in

Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies Genmab secures rights for conducting research on ADCs against multiple drug targets with options for exclusive worldwide development and commercialization of resulting therapies Synaffix to receive an upfront payment of USD $4.5 million with a total deal value of up to USD $415 million plus […]

Read more

Synaffix Announces Expansion of Mersana License Deal to a Total Potential Value Exceeding $1 Billion

/in

Expanded deal focuses on Synaffix’s GlycoConnect™ site-specific ADC bioconjugation technology and adds license options for six new programs to existing deal Mersana currently developing two programs based on GlycoConnect™ site-specific ADC bioconjugation technology (XMT-1592 and XMT-1660) AMSTERDAM, NETHERLANDS, November 30, 2021 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the […]

Read more